Tokyo Tape
Sign in
← Wakamoto Pharmaceutical

Half-year report · HY

4512.TEDINET S100X1U2
Period2025-04-01 → 2025-09-30
Filed2025-11-13
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥4.4bn2025-04-01 → 2025-09-30StandaloneNet sales
Revenue¥7.8bn2024-04-01 → 2025-03-31StandaloneNet sales (5-year summary)
Revenue¥3.8bn2024-04-01 → 2024-09-30StandaloneNet sales
Operating income−¥196m2025-04-01 → 2025-09-30StandaloneOperating income
Operating income−¥277m2024-04-01 → 2024-09-30StandaloneOperating income
Ordinary income−¥176m2025-04-01 → 2025-09-30StandaloneOrdinary income
Ordinary income−¥409m2024-04-01 → 2025-03-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥256m2024-04-01 → 2024-09-30StandaloneOrdinary income
Profit before tax−¥176m2025-04-01 → 2025-09-30StandaloneIncome before income taxes
Profit before tax−¥260m2024-04-01 → 2024-09-30StandaloneIncome before income taxes
Net income−¥134m2025-04-01 → 2025-09-30StandaloneProfit loss
Net income¥64m2024-04-01 → 2025-03-31StandaloneNet income loss (5-year summary)
Net income−¥142m2024-04-01 → 2024-09-30StandaloneProfit loss
Total assets¥14.9bnat 2025-09-30StandaloneAssets
Total assets¥15.0bnat 2025-03-31StandaloneAssets
Total assets¥15.3bnat 2024-09-30StandaloneTotal assets (5-year summary)
Total liabilities¥3.3bnat 2025-09-30StandaloneLiabilities
Total liabilities¥3.4bnat 2025-03-31StandaloneLiabilities
Net assets / equity¥11.6bnat 2025-09-30StandaloneNet assets
Net assets / equity¥11.6bnat 2025-03-31StandaloneNet assets
Net assets / equity¥11.9bnat 2024-09-30StandaloneNet assets (5-year summary)
Cash and deposits¥1.9bnat 2025-09-30StandaloneCash and deposits
Cash and deposits¥3.0bnat 2025-03-31StandaloneCash and deposits
Cash & equivalents¥1.9bnat 2025-09-30StandaloneCash and cash equivalents
Cash & equivalents¥3.0bnat 2025-03-31StandaloneCash and cash equivalents
Cash & equivalents¥3.6bnat 2024-09-30StandaloneCash and cash equivalents
Cash & equivalents¥3.7bnat 2024-03-31vStandaloneCash and cash equivalents
Operating cash flow−¥573m2025-04-01 → 2025-09-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥592m2024-04-01 → 2025-03-31StandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow¥283m2024-04-01 → 2024-09-30StandaloneNet cash provided by used in operating activities
Investing cash flow−¥366m2025-04-01 → 2025-09-30StandaloneNet cash provided by used in investment activities
Investing cash flow−¥13m2024-04-01 → 2025-03-31StandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥225m2024-04-01 → 2024-09-30StandaloneNet cash provided by used in investment activities
Financing cash flow−¥104m2025-04-01 → 2025-09-30StandaloneNet cash provided by used in financing activities
Financing cash flow−¥104m2024-04-01 → 2025-03-31StandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥104m2024-04-01 → 2024-09-30StandaloneNet cash provided by used in financing activities
EPS (basic)¥-3.862025-04-01 → 2025-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥1.852024-04-01 → 2025-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-4.082024-04-01 → 2024-09-30StandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥32024-04-01 → 2025-03-31StandaloneDividend paid per share (5-year summary)
Equity ratio77.9%at 2025-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio77.4%at 2025-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio78.3%at 2024-09-30StandaloneEquity to asset ratio (5-year summary)
Shares issued34,838,000at 2025-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued34,838,000at 2025-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued34,838,000at 2024-09-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Ethical Products Business Relatedreportable segmentrevenue2025-04-01 → 2025-09-30¥2.2bn
Ethical Products Business Relatedreportable segmentrevenue external2025-04-01 → 2025-09-30¥2.2bn
Ethical Products Business Relatedreportable segmentsegment profit2025-04-01 → 2025-09-30−¥446m
Global Sales Development Business Relatedreportable segmentrevenue2025-04-01 → 2025-09-30¥897m
Global Sales Development Business Relatedreportable segmentrevenue external2025-04-01 → 2025-09-30¥897m
Global Sales Development Business Relatedreportable segmentsegment profit2025-04-01 → 2025-09-30¥87m
Otc Products Business Relatedreportable segmentrevenue2025-04-01 → 2025-09-30¥1.2bn
Otc Products Business Relatedreportable segmentrevenue external2025-04-01 → 2025-09-30¥1.2bn
Otc Products Business Relatedreportable segmentsegment profit2025-04-01 → 2025-09-30¥130m
—segment totalrevenue2025-04-01 → 2025-09-30¥4.4bn
—segment totalrevenue external2025-04-01 → 2025-09-30¥4.4bn
—segment totalsegment profit2025-04-01 → 2025-09-30−¥196m
Total Of Reportable Segments And Otherssegment totalrevenue2025-04-01 → 2025-09-30¥4.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2025-04-01 → 2025-09-30¥4.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2025-04-01 → 2025-09-30−¥196m
Ethical Products Business Relatedreportable segmentrevenue2024-04-01 → 2024-09-30¥1.6bn
Ethical Products Business Relatedreportable segmentrevenue external2024-04-01 → 2024-09-30¥1.6bn
Ethical Products Business Relatedreportable segmentsegment profit2024-04-01 → 2024-09-30−¥644m
Global Sales Development Business Relatedreportable segmentrevenue2024-04-01 → 2024-09-30¥905m
Global Sales Development Business Relatedreportable segmentrevenue external2024-04-01 → 2024-09-30¥905m
Global Sales Development Business Relatedreportable segmentsegment profit2024-04-01 → 2024-09-30¥106m
Otc Products Business Relatedreportable segmentrevenue2024-04-01 → 2024-09-30¥1.3bn
Otc Products Business Relatedreportable segmentrevenue external2024-04-01 → 2024-09-30¥1.3bn
Otc Products Business Relatedreportable segmentsegment profit2024-04-01 → 2024-09-30¥230m
—segment totalrevenue2024-04-01 → 2024-09-30¥3.8bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥3.8bn
—segment totalsegment profit2024-04-01 → 2024-09-30−¥277m
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥3.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥3.8bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30−¥277m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 506
ItemContextValueUnit
Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registeredFilingDateInstant_OrdinaryShareMember
Original text (Japanese)東京証券取引所スタンダード市場
Description issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember
Original text (Japanese)権利内容に何ら限定のない当社における標準となる株式であり、単元株式数は100株であります。
Details of employee share option program (text)FilingDateInstantText · Plus
Other information on share acquisition rights (text)FilingDateInstantText · Plus
Exercises etc of moving strike convertible bonds etc (text)FilingDateInstantText · Plus
Changes in number of issued shares stated capital etc (text)FilingDateInstantText · Plus
Major shareholders (text)FilingDateInstantText · Plus
Name major shareholdersInterimInstant_No1MajorShareholdersMember
Original text (Japanese)ロート製薬株式会社
Address major shareholdersInterimInstant_No1MajorShareholdersMember
Original text (Japanese)大阪府大阪市生野区巽西１丁目８番１号
Name major shareholdersInterimInstant_No2MajorShareholdersMember
Original text (Japanese)キッセイ薬品工業株式会社
Address major shareholdersInterimInstant_No2MajorShareholdersMember
Original text (Japanese)長野県松本市芳野19番48号
Name major shareholdersInterimInstant_No3MajorShareholdersMember
Original text (Japanese)AVI JAPAN OPPORTUNITY TRUST PLC（常任代理人　株式会社みずほ銀行 決済営業部）
Address major shareholdersInterimInstant_No3MajorShareholdersMemberText · Plus
Name major shareholdersInterimInstant_No4MajorShareholdersMember
Original text (Japanese)株式会社ブレストシーブ
Address major shareholdersInterimInstant_No4MajorShareholdersMember
Original text (Japanese)大阪府茨木市西駅前町５番10号
Name major shareholdersInterimInstant_No5MajorShareholdersMember
Original text (Japanese)わかもと製薬取引先持株会
Address major shareholdersInterimInstant_No5MajorShareholdersMember
Original text (Japanese)東京都中央区日本橋本町２丁目２番２号
Name major shareholdersInterimInstant_No6MajorShareholdersMember
Original text (Japanese)朝日生命保険相互会社
Address major shareholdersInterimInstant_No6MajorShareholdersMember
Original text (Japanese)東京都新宿区四谷１丁目６番１号
Name major shareholdersInterimInstant_No7MajorShareholdersMember
Original text (Japanese)日本ゼトック株式会社
Address major shareholdersInterimInstant_No7MajorShareholdersMember
Original text (Japanese)東京都新宿区西新宿１丁目26番２号
Name major shareholdersInterimInstant_No8MajorShareholdersMember
Original text (Japanese)株式会社みずほ銀行
Address major shareholdersInterimInstant_No8MajorShareholdersMember
Original text (Japanese)東京都千代田区大手町１丁目５番５号
Name major shareholdersInterimInstant_No9MajorShareholdersMember
Original text (Japanese)アクサ生命保険株式会社
Address major shareholdersInterimInstant_No9MajorShareholdersMember
Original text (Japanese)東京都港区白金１丁目17番３号
Name major shareholdersInterimInstant_No10MajorShareholdersMember
Original text (Japanese)新菱冷熱工業株式会社
Address major shareholdersInterimInstant_No10MajorShareholdersMember
Original text (Japanese)東京都新宿区四谷１丁目６番１号
Issued shares voting rights (text)FilingDateInstantText · Plus
Description issued shares voting rightsInterimInstant_SharesWithNoVotingRightsMember－
Description issued shares voting rightsInterimInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember－
Description issued shares voting rightsInterimInstant_SharesWithRestrictedVotingRightsOtherMember－
Description issued shares voting rightsInterimInstant_SharesWithFullVotingRightsTreasurySharesEtcMember－
Description issued shares voting rightsInterimInstant_SharesWithFullVotingRightsOtherMember－
Description issued shares voting rightsInterimInstant_SharesLessThanOneUnitMember－
Treasury shares etc (text)FilingDateInstantText · Plus
Name of shareholder treasury shares etcInterimInstant_Row1Member
Original text (Japanese)わかもと製薬株式会社
Address of shareholder treasury shares etcInterimInstant_Row1Member
Original text (Japanese)東京都中央区日本橋本町２丁目２番２号
Information about officers (text)FilingDateInstantText · Plus
Regulations in accordance with which financial statements have been prepared financial informationInterimDurationText · Plus
Type1 semi annual financial statements financial informationInterimDurationText · Plus
Note on independent audit financial informationInterimDurationText · Plus
Description of fact that consolidated financial statements have not been prepared financial informationInterimDuration
Original text (Japanese)　当社は、子会社がないため、中間連結財務諸表は作成しておりません。
Type1 semi annual balance sheet (text)InterimDurationText · Plus
Type1 semi annual statement of income (text)InterimDurationText · Plus
Type1 semi annual statement of cash flows (text)InterimDurationText · Plus
Major components of selling general and administrative expenses (text)InterimDuration_NonConsolidatedMemberText · Plus
Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text)InterimDuration_NonConsolidatedMemberText · Plus
Notes regarding dividend (text)Prior1InterimDuration_NonConsolidatedMemberText · Plus
Notes regarding dividend (text)InterimDuration_NonConsolidatedMemberText · Plus
Notes segment information etc type1 semi annual financial statements (text)InterimDurationText · Plus

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identitynon_consolidated 2025-03-31pass rounding
balance sheet identitynon_consolidated 2025-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2025-03-31pass
statement vs summary · net assetsnon_consolidated 2025-09-30pass
statement vs summary · operating cash flownon_consolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flownon_consolidated 2025-04-01/2025-09-30pass
statement vs summary · revenuenon_consolidated 2024-04-01/2024-09-30pass
statement vs summary · revenuenon_consolidated 2025-04-01/2025-09-30pass
statement vs summary · total assetsnon_consolidated 2025-03-31pass
statement vs summary · total assetsnon_consolidated 2025-09-30pass